SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Corey J. Langer, Mary W. Redman, James L. Wade, Charu Aggarwal, Jeffrey D. Bradley, Jeffrey Crawford, Philip J. Stella, Mark H. Knapp, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Karen Kelly, David R. Gandara, Vassiliki A. Papadimitrakopoulou
Dive into the research topics of 'SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)'. Together they form a unique fingerprint.